Targeted Oncology Staff

During a live virtual event, Richard S. Finn, MD, discussed the process of diagnosing liver cancer after a CT scan detected tumors and whether a biopsy was needed.

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.

During a live virtual event, Ravi Salgia, MD, PhD, discussed a possible approach for biopsy and molecular testing of a patient diagnosed with lung adenocarcinoma.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 PROSPER trial of enzalutamide and the phase 3 ARAMIS trial of darolutamide in patients with castration-resistant prostate cancer.

During a live virtual event, Paolo Caimi, MD, discussed third-line treatment of a patient with diffuse large B-cell lymphoma and navigating obstacles to treatment.

Six months after a 75-year-old patient with castration-resistant prostate cancer shows undetectable PSA, the patient developed new hip pain and urinary frequency.

During a live virtual event, Beth A. Christian, MD, discussed data on third-line loncastuximab tesirine treatment in patients with diffuse large B-cell lymphoma and how to sequence treatments for patients who may receive CAR T-cell therapy.

Oncologists discuss a 59-year-old man with poorly differentiated adenocarcinoma of the lung.

The case of a 51-year-old with multiple myeloma, standard risk, stage II was the topic of discussion during a recent Targeted Oncology Case-Based Roundtable moderated by Ajai Chari, MD.

Following 6 well-tolerated cycles of R-CHOP, a 75-year-old patient with diffuse large B-cell lymphoma showed complete remission on a PET scan. But 1 year later, the disease relapsed.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 SPARTAN trial of apalutamide in patients with castration-resistant prostate cancer.

Based on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.

A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma.

Treatment for a patient with poorly differentiated adenocarcinoma of the lung was the topic of discussion between Joshua K. Sabari, MD and peers during a Case-Based Roundtable.

During a live virtual event, Beth A. Christian, MD, discussed real-world challenges of providing timely access to CAR-T cell therapy for patients with diffuse large B-cell lymphoma.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer.

During a live virtual event, Beth A. Christian, MD, discussed approaches to third-line treatment of transplant-ineligible DLBCL and when to consider CAR T-cell therapy.

During a live virtual event, Martin Dietrich, MD, PhD, discusses how to address switching treatments in response to detection of a MET gene biomarker.

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

During a live virtual event, Martin Dietrich, MD, PhD, discusses management of toxicities and adverse events of MET inhibitors in non–small cell lung cancer.

A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.

During a live virtual event, Danielle Brander, MD, discussed with participating physicians second-line treatment options for patients with chronic lymphocytic leukemia, with questions guided by Targeted Oncology.

A 66-year-old woman was referred by urology after evaluation for gross hematuria. After a clinical work-up, the patient was diagnosed with metastatic bladder cancer.

At a live virtual event, Martin Dietrich, MD, PhD, discusses treatment options for a patient with non–small cell lung cancer when molecular testing shows a MET exon 14 skipping mutation.

During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, led a discussion about treatment of patients with EGFR-mutant non–small cell lung cancer.

A 75-year-old man presented with intermittent right hip pain, but his physical examination was unremarkable and he had an ECOG performance score of 1. Two oncologists lead a discussion about the patient's case.

A group of oncologists led by Bradley C. Carthon, MD, PhD, discussed clinical work-up, treatment, and follow-up for a 75-year old patents with castration-resistant prostate cancer.

Eleven months after a 43-year-old woman with diffuse large B-cell lymphoma completed chimeric antigen receptor T-cell therapy, she complained of fever, night sweats, and back pain.

At a live virtual event, Martin Dietrich, MD, PhD, discusses how to approach biopsies and molecular testing in coordination with pathologists and testing services for patients with non–small cell lung cancer.

The biopsy of a 88-year-man demonstrated infiltrative basal cell carcinoma. his case was the topic of discussion during a Case-Based Roundtable led by Nikhil I. Khushalani, MD.